EverPoint Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

EverPoint Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-600,000	Closed	-$1.66M	–	411
2016 Q2	$1.66M	Hold	600,000	–	–	0.03%	330
2016 Q1	$1.75M	Sell	600,000 -59,210	-9%	-$143K	0.03%	350
2015 Q4	$1.63M	Hold	659,210	–	–	0.03%	397
2015 Q3	$1.87M	Buy	+659,210	New	+$2.26M	0.05%	337

Other funds holding AUPH

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

EverPoint Asset Management's AUPH Position: Q3 2016 in Review

EverPoint Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2016, closing a stake of 600,000 shares — an estimated $1.66M sold.

EverPoint Asset Management first reported a position in AUPH in Q3 2015 and held it in 4 quarters. The position peaked at $1.87M in Q3 2015. 15 funds tracked by Wall St. Rank hold AUPH as of Q3 2016.

EverPoint Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
EverPoint Asset Management sold 600,000 Aurinia Pharmaceuticals shares in Q3 2016, an estimated $1.66M.
EverPoint Asset Management first reported a position in Aurinia Pharmaceuticals in Q3 2015 and held it in 4 quarters.
EverPoint Asset Management's Aurinia Pharmaceuticals position peaked at $1.87M in Q3 2015.
15 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2016.

Based on EverPoint Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.